KULDEEP SHARMA

• General Acute (Anti-microbials, Hematinics, Probiotics etc.)
• Division : Nutrakare - 1
• Portfolio size : 160 Cr
• Growth Rate % : 27 % in FY 21-22
• Team Size : 1 GPM, 2 PMs, 2 APMs & 1MT
• Achievements : SBU is consistently performing (99.4% in 2017-18, 95.63% in 2018-19, 89.12% in 2019-20, 93.07% in 2020-21, 106.13% in 2021-22)
• Handling biggest SBU of Medley with 160 Cr turnover. R B TONE - major brand of the division gained 1 rank in IMS and achieved 2nd rank for the first time in Liquid Hematinic market and has reported highest Rx growth among top 10 brands as per SMSRC. Volume moved from 40 Crs in 2018 to 93 Crs in 2022 (IMS MAT MAR'22) with 16.5% CAGR. Another major brand of SBU (O2 Suspension) gained 1st rank after formulation change in Ofloxacin+Metronidazole Liq. market) with 30 Cr value
• Recognition: Got two internal promotions (DGM to GM Marketing in 2019 and GM to Sr. GM in 2022)

Organization &Turnover : FDC Limited & 250 Cr, Segments : General Acute (Antibiotics)

• Growth : 16%
• Portfolio Size : 250 Cr
• Achievements : Successfully established Zifi Turbo in the market with highest internal Gr of 56 %
• Enerzal showed highest unit growth Internal & AWACS in last 10 Years (78 %) : Zifi 200 gained No.1 position amongst Phy & Surg with highest Rxs growth

• Chronic (Urology )
• Products : Cranpac-D, Bacstol, Nifutin
• Portfolio size : 8 Cr
• Achievements : Successfully launched Bacstol (Trimethoprim Plain ) for 1st time in India

Segment: Acute (Anti-cold, Macrolides, Cough Preparations)

• Products : Wikoryl, Brozeet, Brozeet-LS , Panplus
• Portfolio Size : 55 Cr
• Achievements : Successfully Launched Panplus- l, Brozeet-LS & Wikoryl ND
• Brozeet LS became 3 Cr brand & Panplus-L became 2.75 Cr brand in first year of launch

• Achievements : No.1 Regional Manager in sales with highest % Ach (Delhi & Rajasthan)

• Achievements : Took two internal promotions because of consistent performance.